TargetMol

AZD-1480

Product Code:
 
TAR-T3069
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T3069-50mg50mgEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3069-5mg5mg£112.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3069-1mL1 mL * 10 mM (in DMSO)£114.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3069-10mg10mg£136.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3069-25mg25mg£185.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
AZD1480 is a novel ATP-competitive JAK2 inhibitor (IC50: 0.26 nM), selectivity act against Tyk2 and JAK3, and to a smaller extent against JAK1. AZD1480 has been used in trials studying the treatment of Solid Malignancies, Post-Polycythaemia Vera, Primary Myelofibrosis (PMF), and Essential Thrombocythaemia Myelofibrosis.
CAS:
935666-88-9
Formula:
C14H14ClFN8
Molecular Weight:
348.77
Pathway:
JAK/STAT signaling; Stem Cells; Angiogenesis; Chromatin/Epigenetic
Purity:
0.9855
SMILES:
C[C@H](Nc1ncc(Cl)c(Nc2cc(C)[nH]n2)n1)c1ncc(F)cn1
Target:
JAK

References

1. E Derenzini, et al. Blood Cancer J, 2011, 1(12), e46. 2. Scuto A, et al. Leukemia, 2011, 25(3), 538-50. 3. McFarland BC,et al. Cancer Ther, 2011, 10(12), 2384-93. 4. Xin H, et al. Cancer Res, 2011, 71(21), 6601-10. 5. Hedvat M, et al. Cancer Cell, 2009, 16(6), 487-97. 6. Ni J, et al. Tyrosine receptor kinase B is a drug target in astrocytomas. Neuro Oncol. 2017 Jan;19(1):22-30. 7. Yang, Tianfeng, Xianpeng Shi, Yuan Kang, Man Zhu, Mengying Fan, Dongdong Zhang, and Yanmin Zhang. Novel compounds TAD-1822-7-F2 and F5 inhibited HeLa cells growth through the JAK/Stat signaling pathway [J]. Biomedicine & Pharmacotherapy . 2018 Jul;103:118-126.